Anthony Nolan Research Institute, London, United Kingdom.
University College London, London, United Kingdom.
Front Immunol. 2018 Feb 13;9:252. doi: 10.3389/fimmu.2018.00252. eCollection 2018.
Regulatory T cells (Tregs) are CD4 T cells that are key players of immune tolerance. They are powerful suppressor cells, able to impact the function of numerous immune cells, including key effectors of inflammation such as effector T cells. For this reason, Tregs are an ideal candidate for the development of cell therapy approaches to modulate immune responses. Treg therapy has shown promising results so far, providing key knowledge on the conditions in which these cells can provide protection and demonstrating that they could be an alternative to current pharmacological immunosuppressive therapies. However, a more comprehensive understanding of their characteristics, isolation, activation, and expansion is needed to be able design cost effective therapies. Here, we review the practicalities of making Tregs a viable cell therapy, in particular, discussing the challenges faced in isolating and manufacturing Tregs and defining what are the most appropriate applications for this new therapy.
调节性 T 细胞(Tregs)是 CD4 T 细胞,是免疫耐受的关键参与者。它们是强大的抑制性细胞,能够影响众多免疫细胞的功能,包括炎症的关键效应物,如效应 T 细胞。出于这个原因,Tregs 是开发细胞治疗方法来调节免疫反应的理想候选者。Treg 治疗迄今为止已经显示出了有希望的结果,为这些细胞在哪些情况下可以提供保护提供了关键知识,并证明它们可能是当前药物免疫抑制治疗的替代方法。然而,为了能够设计出具有成本效益的治疗方法,需要更全面地了解它们的特性、分离、激活和扩增。在这里,我们综述了将 Tregs 作为可行的细胞治疗方法的实际情况,特别是讨论了在分离和制造 Tregs 方面面临的挑战,并确定了这种新疗法最适合的应用。